| Original language | English (US) |
|---|---|
| Pages (from-to) | 2396-2398 |
| Number of pages | 3 |
| Journal | Annals of Oncology |
| Volume | 29 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2018 |
ASJC Scopus subject areas
- Hematology
- Oncology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Annals of Oncology, Vol. 29, No. 12, 12.2018, p. 2396-2398.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials
AU - Sen, S.
AU - Carmagnani Pestana, R.
AU - Hess, K.
AU - Viola, G. M.
AU - Subbiah, V.
N1 - Funding Information: The University of Texas MD Anderson Cancer Center is supported by the National Institutes of Health Cancer Center Support Grant CA016672. The University of Texas MD Anderson Cancer Center clinical trials program is supported in part by Cancer Prevention Research Institute of Texas Grant RP110584 and National Center for Advancing Translational Sciences Grant UL1 TR000371 (Center for Clinical and Translational Sciences). Funding Information: The University of Texas MD Anderson Cancer Center is supported by the National Institutes of Health Cancer Center Support Grant CA016672. The University of Texas MD Anderson Cancer Center clinical trials program is supported in part by Cancer Prevention Research Institute of Texas Grant RP110584 and National Center for Advancing Translational Sciences Grant UL1 TR000371 (Center for Clinical and Translational Sciences). VS receives research funding for clinical trials from LOXO oncology Roche/Genentech, Novartis, Bayer, GSK, Nanocarrier, Vegenics, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, Pharmamar, D3, Pfizer, Multivir, Amgen, Abbvie, and Blueprint medicines. All remaining authors have declared no conflicts of interest. National Institutes of Health Cancer CenterCA016672, The University of Texas MD Anderson Cancer Center, Cancer Prevention Research Institute of TexasRP110584, National Center for Advancing Translational SciencesUL1 TR000371
PY - 2018/12
Y1 - 2018/12
UR - http://www.scopus.com/inward/record.url?scp=85059290786&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059290786&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdy453
DO - 10.1093/annonc/mdy453
M3 - Letter
C2 - 30307530
AN - SCOPUS:85059290786
SN - 0923-7534
VL - 29
SP - 2396
EP - 2398
JO - Annals of Oncology
JF - Annals of Oncology
IS - 12
ER -